JPMorgan analyst Kenneth Worthington upgraded CME Group to Overweight citing the 15% pullback in shares since the December 15 and benefits from elevated volatility in the markets. The analyst has a $96 price target for the shares.

BofA raised the firm's price target on CME Group to $216 from $209 and keeps a Neutral rating on the shares after the company reported adjusted EPS that beat the firm's estimate and the consensus due to lighter compensation expense. While CME demonstrated its ability to drive volumes against a challenging macroeconomic backdrop with multi-year lows in volatility, soft pricing detracted from the favorable volume result, says the analyst, who also highlights "buyside skepticism" of CME's ability to defend its share in rates futures from BGC's FMX platform.

Barclays analyst Benjamin Budish raised the firm's price target on CME Group to $228 from $226 and keeps an Equal Weight rating on the shares. The company's Q1 earnings beat by 1%, driven by both better than expected revenues and lower than expected costs, and the tone of the call was positive, the analyst tells investors in a research note.